跳至主導覽
跳至搜尋
跳過主要內容
臺北醫學大學 首頁
說明與常見問題
English
中文
首頁
專家檔案
研究單位
專案
研究成果
資料集
活動
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
宋 睿祥
助理教授
,
一般外科
主治醫師
,
臺北市立萬芳醫院
副主任
,
臺北醫學大學器官移植研究中心
成員
,
臺北醫學大學消化醫學研究中心
成員
,
臺北醫學大學泌尿腎臟研究中心
電子郵件
111149
w.tmu.edu
tw
h-index
606
引文
15
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2009
2024
每年研究成果
概覽
指紋
網路
研究成果
(42)
類似的個人檔案
(6)
指紋
查看啟用 Ruey-Shyang Soong 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Medicine and Dentistry
Liver Transplantation
100%
Hepatocellular Carcinoma
42%
Hepatectomy
28%
Liver Graft
25%
Neoplasm
24%
Surgery
15%
Meta-Analysis
13%
Hepatitis B
13%
Piperidone Derivative
13%
CD8 Antigen
11%
Overall Survival
11%
Model For End Stage Liver Disease Score
10%
End Stage Liver Disease
10%
Survival Rate
10%
Malignant Neoplasm
10%
Proteasome
10%
Acute Graft Rejection
9%
Cytotoxic T-Cell
9%
Infection
9%
Carcinoma Cell
8%
Recurrence Risk
8%
T Cell
8%
Cancer
8%
Immunosuppressive Treatment
8%
Immunosuppressive Drug
8%
Body Mass Index
7%
Tumor Microenvironment
7%
Bortezomib
7%
Gastrointestinal Bleeding
6%
Common Hepatic Artery
6%
Fistula
6%
Humoral Rejection
6%
Omentectomy
6%
Propensity Score Matching
6%
Underweight
6%
Herniorrhaphy
6%
Seroma
6%
Toll Like Receptor Agonist
6%
Systematic Review
6%
Scoring System
6%
Antigen Specificity
6%
Alternative Complement Pathway C3 C5 Convertase
6%
Antifungal Agent
6%
Nuclear Factor
6%
Cell Count
6%
Mycosis
6%
Imiquimod
6%
Heterotopic
6%
Observational Study
6%
Betel
6%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
35%
Neoplasm
26%
Mouse
21%
CD8 Antigen
20%
End Stage Liver Disease
18%
Vaccination Policy
17%
Malignant Neoplasm
16%
Piperidone Derivative
13%
Non Insulin Dependent Diabetes Mellitus
13%
Mycosis
13%
Proteasome
9%
Acute Graft Rejection
9%
Human Papillomavirus
9%
Ovary Cancer
8%
Overall Survival
8%
DNA Vaccine
8%
Tumor Microenvironment
7%
Mouse Model
7%
Histamine H1 Receptor Antagonist
6%
Hernia
6%
Seroma
6%
Toll Like Receptor Agonist
6%
Infection
6%
Histone Deacetylase Inhibitor
6%
Antifungal Agent
6%
Chronic Kidney Failure
6%
Hepatitis B
6%
Vaccinia Vaccine
6%
Short Term Survival
6%
Antihistaminic Agent
6%
Protein P53
6%
Stomach Cancer
6%
Cisplatin
6%
Nuclear Factor
6%
Alternative Complement Pathway C3 C5 Convertase
6%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
6%
Decompensated Liver Cirrhosis
6%
Observational Study
6%
Deterioration
6%
Hip Fracture
6%
Imiquimod
6%
Carcinoma
6%
Tacrolimus
6%
Ulcer Perforation
6%
Ascites
6%
Long Term Survival
6%
Ubiquitin
6%
Disease Free Survival
6%
Survival Rate
5%
Tumor Growth
5%
Immunology and Microbiology
Liver Transplantation
48%
Cytotoxic T-Cell
34%
Mouse
30%
Proteasome
22%
Immune Tolerance
13%
DNA Vaccination
13%
Antigen Specificity
12%
Survival Rate
11%
Tumor Antigen
11%
Overall Survival
10%
Wart Virus
10%
Human Papillomavirus Type 16
9%
T Cell
9%
Immune Response
9%
Myeloid-Derived Suppressor Cell
8%
P53
8%
DNA Vaccine
8%
Mouse Model
8%
Endoplasmic Reticulum Stress
8%
Electroporation
7%
Immunosuppression
7%
Transplant Procedure
6%
Viral Load
6%
CD4 CD8 Ratio
6%
Cancer Cell Line
6%
Blood Group ABO Incompatibility
6%
Complement Factor B
6%
Immunocompetent Cell
6%
Vaccinia Vaccine
6%
Disease Free Survival
6%
Cellular Distribution
6%
Body Mass
6%
Long Term Survival
6%
T Cell Activation
6%
CD40 Ligand
6%
Agonist
6%
Toll-Like Receptor
6%
Imiquimod
6%
Hepatitis B
6%
Molecular Weight
5%
Rituximab
5%
Vaccination Policy
5%
Blood Plasma
5%
Syngenic
5%
